Stock Spotlight: Cochlear Limited (ASX:COH)
This week's Stock Spotlight is ASX-listed Cochlear Limited.
About Cochlear Limited.
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor and Baha implant; and accessories, such as wireless devices and Nucleus water-safe accessories. The company was founded in 1981 and is headquartered in Sydney, Australia.
Source: EODHD
Key Stats
Key Stats
Source: EODHD. Data as of 24/04/26.
Price Performance
Growth Potential
- Share price & trading multiples have materially de-rated post the latest earnings downgrade and are now trading on undemanding metrics subject to no further earnings downgrades.
- The key concern for investors from the update was the slowdown in sales in COH’s key adult & seniors’ segment in developed markets. Management believes COH’s sales correlate more closely with consumer sentiment – which is at an all-time low in the U.S. – than previously seen. This raises questions about the defensive nature of COH’s sales, given that consumers and hospitals are “deprioritizing” Cochlear Implant (CI) surgeries.
- Management believes they can return to delivering CI volumes growth of +10% p.a. and is still targeting NPAT margin of 18% over the medium term.
- Market leading positions globally.
- Best in class R&D program (significant dollar amount) leading to continual development of new products and upgrades to existing suite of products.
- New product launches – the launch of Nucleus Nexa is in line with expectations
- Solid balance sheet position.
Key Risks
- Product recall.
- R&D program fails to deliver innovative products.
- Increase in competitive pressures.
- Change in government reimbursement policy.
- Adverse movements in AUD/USD.
- Emerging market does not recoup – significant downside to earnings.
Subscribe to our newsletter
Disclaimer: This article does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.
Speak to an Advisor
